Market Overview

UPDATE: Bank of America Lowers Auxilium Pharmaceuticals PO to $25 Following 4Q12 Results

Related AUXL
Drug ETFs Attractive Buys On Pullback
Auxilium Pharmaceuticals, Inc. Announces XIAFLEX Now Approved For The Concurrent Treatment Of Up To Two Affected Joints In The Same Hand In Dupuytren's Contracture Patients

Bank of America published a report that reiterated Auxilium Pharmaceuticals (NASDAQ: AUXL) at Buy and trims price objective from $26 to $25.

Bank of America reported that, “We lowered our market growth assumptions for Testim based on recent Rx trends, and modestly increased our share estimates, which assume that AUXL's efforts to stabilize and grow share in 2013 are successful. These changes reduced our 2013E Testim sales to $252mn (from $257mn) and increased our 2014E sales to $302mn (from $293mn). We also lowered our Xiaflex sales estimates for 2013E to $71mn (from $85mn) and $104mn (from $119mn). Our new 2013E EPS is $0.15 (from $0.44) and our 2014E EPS is $0.98 (from $1.02).”

Auxilium Pharmaceuticals shares closed Tuesday at $17.06.

Latest Ratings for AUXL

Oct 2014MKM PartnersDowngradesBuyNeutral
Oct 2014MizuhoDowngradesBuyNeutral
Sep 2014RBC CapitalDowngradesOutperformSector Perform

View More Analyst Ratings for AUXL
View the Latest Analyst Ratings

Posted-In: Bank of AmericaAnalyst Color Price Target Analyst Ratings


Related Articles (AUXL)

View Comments and Join the Discussion!